PERSONAL INFORMATION

Andrea Bertotti

University of Torino
Department of Oncology
Strada Provinciale 142, km 3.95, 10060 Candiolo, Torino, Italy

+39 011 993-32-27

andrea.bertotti@unito.it

SCOPUS ID: 6603084027
ORDID: 0000-0001-8196-7608

Male | *20/01/1977* | *Italian*

WORK EXPERIENCE

2017 – present

Associate Professor

University of Torino, Torino, Italy

- Co-Head, Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment, Candiolo

Basic and applied research

2010 – 2017

Assistant Professor

University of Torino, Torino, Italy

- Researcher, Division of Molecular Oncology, Institute for Cancer Research and Treatment, Candiolo

Basic and applied research

EDUCATION AND TRAINING

2001 – 2006

Ph.D. (Doctor of Philosophy)

University of Torino, Torino, Italy

- Cellular biology and technology

1995 – 2001

M.D. (Medical Doctor)

University of Torino, Torino, Italy

- Biomedicine

WORK ACTIVITIES

Awards

2017: ERC Consolidator Grant – ERC
2015: Andrea e Libi Lorini award, early careers in oncology – Fondazione Lorini
2014: NextGenStar award – AACR.
2012: Fight Colorectal Cancer award in memory of Lisa Dubow, Career development award – AACR.
2014: AIRC Comitato Tecnico Scientifico – Member
2007: Lucatello e Mazzega award – AIRC (Associazione Italiana per la Ricerca sul Cancro).

Editorial activity

Ad-hoc peer-reviewer for Nature Pathway Interaction Database, Journal of Cell Biology, Cancer Research, Clinical Cancer Research, Oncogene, Journal of Cell Science, BMC Cancer, Journal of Biological Chemistry, Cancer Prevention Research, Breast Cancer Research, Molecular Cancer, Molecular Oncology, PLoS One, Cancer Letters, Journal of Clinical Pathology, Faseb Journal, Carcinogenesis.

Invited presentations

2017: EACR-AACR-SIC. June 24-27, Florence, Italy.
2017: Charles River's 8th European Short Course. March 22-24, Berlin, Germany.
2016: EurOPDX meeting 2016. October 3-5, Weggis, Switzerland.
2016: AACR Special Conference on Patient Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic. February 11-14, New Orleans, LA.
2014: AACR Annual meeting 2014a. April 5-9, San Diego, CA.
2014: AACR Annual meeting 2014b. April 5-9, San Diego, CA.
2014: Charles River's 7th European Short Course. February 12-14, Strasbourg, France.
2012: NSABP Annual Division of Industry Trials Fall Investigator Meeting. October 18-19,Chicago, IL.

Grants

2018 – 2025: AIRC Multi-Unit Project '5 per mille' 21091
2018 – 2021: EU Horizon 2020 731105 EDIReX
2018 – 2022: AIRC IG 20697
2017 – 2023: ERC CoG 724748 BEAT
2015 – 2017: AIRC IG 15571
2013 – 2014: AACR 12-20-16-BERT, FIGHT COLORECTAL CANCER
2010 – 2013: MIUR FIRB RBFR082XL7

ADDITIONAL INFORMATION

Publications

Number of total publications in peer-review journals in the last ten years (2012-2022): 73
Total number of citations: 8433 (Scopus)
H index:: 41 (Scopus)

Selected recent publications:

1. Jaaks P et al. Effective drug combinations in breast, colon and pancreatic cancer cells. *Nature* **603**:166-173, 2022.
2. Tedesco M et.al. Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin. *Nat. Biotechnol.* **40**:235-244, 2022 doi: 10.1038/s41587-021-01031-1.
3. Ponsioen B et al.. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. *Nat. Cell Biol*. **23**:377-390, 2021. doi: 10.1038/s41556-021-00654-5
4. Woo XY et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. *Nat. Genet*. **53**:86-99, 2021. doi: 10.1038/s41588-020-00750-6
5. Lupo B et al. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. *Sci. Transl. Med*. **12**:eaax8313, 2020. doi: 10.1126/scitranslmed.aax8313. *** Co-enior and corresponding author**
6. Russo M et al. Adaptive mutability of colorectal cancers in response to targeted therapies. *Science* **366**:1473-1480, 2019.
7. Behan FM et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. *Nature* **568**:511-516, 2019. doi: 10.1038/s41586-019-1103-9
8. Siravegna G et al.. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. *Cancer Cell* **34**:148-162, 2018. doi: 10.1016/j.ccell.2018.06.004. * **Co-senior author**
9. Isella C et al.. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. *Nat. Commun*. **8**:15107, 2017. doi: 10.1038/ncomms15107.*** Senior and corresponding author**
10. Sartore-Bianchi A et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol*. **17**:738-746, 2'16. doi: 10.1016/S1470-2045(16)00150-9.
11. Bertotti A et al. The genomic landscape of response to EGFR blockade in colorectal cancer. *Nature* **526**:263-267, 2015. doi: 10.1038/nature14969. *** Corresponding author**
12. Zanella ER et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. *Sci. Transl. Med*. **7**:272ra12, 2015. doi: 10.1126/scitranslmed.3010445. ***Senior and corresponding author**